Insight2016-08-01T14:51:33-04:00
  • The BioSig Technologies logo

Laidlaw served as Sole Book-Runner on the $10mm BioSig Technologies (BSGM) Follow-On Offering.

February 21st, 2020|Comments Off on Laidlaw served as Sole Book-Runner on the $10mm BioSig Technologies (BSGM) Follow-On Offering.

Laidlaw Capital Markets is pleased to announce today's pricing of a $10,000,000 Follow-On Offering for BioSig Technologies (BSGM). Laidlaw proudly served as the Sole Book Runner on the transaction. See full Press Release on BioSig Website Read More...

Defiance ETFs LLC Rings The Closing Bell®

February 7th, 2020|Comments Off on Defiance ETFs LLC Rings The Closing Bell®

Laidlaw was proud to attend the closing bell ceremony at the NYSE yesterday. Defiance ETFs LLC is the first 5G ETF (NYSE Arca: FIVG) Alex Shtaynberger, Richard Calhoun and Keith Hassan from Laidlaw attended and were Read More...

Laidlaw served as Co-Manager on the $90mm Ziopharm Oncology (ZIOP) Follow-On Offering

February 5th, 2020|Comments Off on Laidlaw served as Co-Manager on the $90mm Ziopharm Oncology (ZIOP) Follow-On Offering

Laidlaw Capital Markets is pleased to announce today’s pricing of a $90,000,000 Follow-On Offering for Ziopharm Oncology (ZIOP). Laidlaw proudly served as Co-Manager alongside Jefferies, who was Sole-Book Runner on the transaction. See full Press Read More...

2506, 2020

Laidlaw served as Co-Manager on the $50,000,000 Follow-On Offering for Soleno Therapeutics (SLNO) with Guggenheim Partners

By |June 25th, 2020|News|

Laidlaw is pleased to have Co-Managed a $50,000,000 deal for Soleno Therapeutics (SLNO) with Guggenheim Partners. View Press Release

1506, 2020

Laidlaw Venture Partners Adds Industry Leading CEOs Jeffrey O’Donnell and Dr. Ann Marie Sastry to its Board of Advisors

By |June 15th, 2020|News, press release|

Laidlaw Venture Partners, the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the addition of Jeffrey O'Donnell and Dr. Ann Marie Sastry to its Board of Advisors. With more than 50 years of combined experience in leading companies across medical devices and artificial intelligence (AI) technology, O'Donnell and Sastry will help guide Laidlaw Venture Partners in building and expanding its already diverse portfolio of innovative companies.

Ready to talk?

Lorem ipsum dolor sit amet, consectetur adipisicing elit mod tempor incididunt ut labore et dolore magna aliqua.

Go to Top